[ad_1] Massimo Cristofanilli, MD The association palbociclib (Ibrance) and fulvestrant (Faslodex) resulted in a clinically significant benefit in terms of overall survival (OS) in patients with advanced HER2-negative breast cancer presenting with …
Read More »The benefit of OS confirmed with the Palbociclib combo in HR + / HER2 breast cancer pre-treated
